Saturday 17 October 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.83
0.69
−6.56%
Follow PBYI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
8 | 5 | 6 | 4 | 4 | 4 | 5 | — | — | — |
P/E ratio |
9.44 | 5.00 | 9.85 | 1,966.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
1.30 | 0.64 | 0.91 | 0.81 | 0.49 | 1.80 | 1.25 | 3.08 | 0.00 | — |
Altman Z-Score |
(4.16) | (6.05) | (5.69) | (6.36) | (6.82) | (6.03) | (5.68) | (4.04) | 5.12 | — |
P/FCF ratio |
10.18 | 5.64 | 14.88 | 0.00 | 12.00 | 0.00 | 15.78 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(14.13) | (16.73) | (16.14) | (17.56) | (18.76) | (17.86) | (16.66) | (13.98) | (30.90) | — |
Beneish M-Score |
(2.06) | (2.90) | (2.45) | (1.81) | (3.27) | (3.57) | (3.91) | 2.20 | — | — |
P/Operating CF |
20.64 | 9.51 | 20.42 | 24.02 | (22.73) | (72.06) | 216.62 | 109.57 | (96.71) | — |
P/B ratio |
2.28 | 1.61 | 4.00 | 8.54 | 0.00 | 0.00 | 19.43 | 22.51 | 64.61 | — |
Price to Tangible BV |
3.35 | 3.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 696.13 | — |
EV/Sales |
1.01 | 0.50 | 0.92 | 0.90 | 0.53 | 1.79 | 1.16 | 3.02 | 0.00 | — |
EV/EBITDA |
4.80 | 2.69 | 4.92 | 6.13 | 10.58 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
5.53 | 2.94 | 8.04 | (13.01) | 6.45 | 520.21 | 14.14 | (31.47) | (19.77) | — |
EV/FCF |
7.91 | 4.35 | 15.14 | (8.88) | 12.94 | (41.98) | 14.71 | (30.69) | (19.73) | — |
Quick Ratio |
1.89 | 1.38 | 1.45 | 1.57 | 1.13 | 1.12 | 1.64 | 2.77 | 1.57 | 6.13 |
Current Ratio |
2.00 | 1.54 | 1.57 | 1.73 | 1.28 | 1.28 | 1.83 | 3.02 | 1.82 | 6.31 |
Net Debt/EBITDA |
(1.60) | (0.80) | 0.08 | 0.64 | 0.77 | 0.19 | 0.74 | 0.16 | 0.11 | 0.83 |
Debt/Assets |
10.41% | 31.43% | 43.23% | 46.14% | 44.43% | 40.26% | 41.54% | 58.62% | 29.29% | 0.00% |
Debt/Equity |
0.17 | 0.73 | 1.86 | 4.74 | (41.16) | (16.52) | 5.59 | 4.43 | 0.91 | 0.00 |
Asset Turnover |
1.06 | 1.04 | 1.04 | 1.02 | 1.08 | 0.94 | 1.10 | 1.18 | 0.13 | 0.00 |
Operating CF/Net income |
1.34 | 1.29 | 1.25 | (7,913.50) | (0.71) | (0.01) | (0.30) | 0.21 | 0.59 | 0.51 |
Capex/Depreciation |
(0.01) | 0.00 | (1.10) | (0.71) | 0.00 | (1.00) | (0.04) | (0.08) | (17.94) | (6.34) |
Interest Coverage |
5.63 | 2.49 | 2.45 | 2.05 | 0.10 | (2.16) | (2.60) | (8.62) | (406.10) | (288.72) |
| 27.97% | 41.60% | 57.54% | 0.02% | 693.73% | (1,042.29%) | (292.05%) | (259.28%) | (221.91%) | (132.75%) | |
| 14.48% | 13.64% | 9.54% | 0.00% | (12.37%) | (25.04%) | (30.60%) | (53.49%) | (139.59%) | (112.06%) | |
ROIC |
43.78% | 33.25% | 35.69% | 34.49% | 11.10% | 0.00% | 0.00% | (284.82%) | (910.03%) | 0.00% |
Return on Tangible Assets |
38.12% | 58.16% | 37.45% | 0.00% | (90.48%) | (174.58%) | (95.98%) | (81.21%) | (555.85%) | (135.19%) |
Average Days of Receivables |
85.75 | 50.70 | 74.10 | 64.59 | 46.90 | 41.42 | 38.74 | 30.21 | 127.49 | — |
Research and Development Expense of Revenue |
27.18% | 23.84% | 21.38% | 22.91% | 28.39% | 43.38% | 48.80% | 65.68% | 750.62% | 0.00% |
Selling, General and Administrative Expense of Revenue |
31.02% | 34.78% | 38.17% | 39.46% | 45.94% | 52.64% | 52.02% | 58.24% | 385.38% | 0.00% |
Intangible Assets out of Total Assets |
0.19 | 0.24 | 0.26 | 0.32 | 0.29 | 0.30 | 0.17 | 0.17 | 0.29 | 0.00 |
Share Based Compensation of Revenue |
3.04% | 3.58% | 4.35% | 5.19% | 12.89% | 16.25% | 21.06% | 34.64% | 392.76% | 0.00% |
Graham Net Nets |
0.26 | 0.18 | (0.10) | (0.36) | (0.72) | (0.26) | (0.15) | (0.03) | 0.00 | — |
Graham Number |
6.08 | 5.10 | 3.43 | 0.15 | 0.98 | 2.26 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
10.59% | 20.00% | 10.15% | 0.05% | (23.36%) | (14.72%) | (22.40%) | (14.69%) | (8.47%) | — |
Free Cash Flow Yield |
9.82% | 17.74% | 6.72% | (12.56%) | 8.34% | (2.36%) | 6.34% | (3.20%) | (5.02%) | — |
Revenue per Share |
4.57 | 4.74 | 5.00 | 5.10 | 6.23 | 5.69 | 7.02 | 6.62 | 0.74 | 0.00 |
Operating CF per Share |
0.84 | 0.80 | 0.57 | (0.35) | 0.51 | 0.02 | 0.58 | (0.64) | (4.64) | (4.26) |
Capex per Share |
0.00 | 0.00 | (0.27) | (0.16) | 0.00 | (0.25) | (0.01) | (0.02) | (1.36) | (0.22) |
Free Cash Flow per Share |
0.83 | 0.80 | 0.30 | (0.51) | 0.51 | (0.23) | 0.57 | (0.65) | (6.00) | (4.47) |
Cash per Share |
1.99 | 2.08 | 2.04 | 1.81 | 2.24 | 2.58 | 3.11 | 4.36 | 2.20 | 6.89 |
Shareholders Equity per Share |
2.61 | 1.89 | 1.13 | 0.48 | (0.06) | (0.15) | 0.45 | 0.90 | 1.43 | 6.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.61 | 1.89 | 1.13 | 0.48 | (0.06) | (0.15) | 0.45 | 0.90 | 1.43 | 6.30 |
Free Cash Flow |
41.73 | 38.86 | 14.37 | (22.83) | 20.65 | (9.27) | 22.07 | (24.71) | (222.90) | (148.97) |
Working Capital |
81.43 | 51.55 | 56.80 | 56.80 | 30.44 | 31.88 | 75.46 | 135.89 | 48.05 | 199.01 |
Capital Expenditures |
(0.07) | (0.06) | (12.64) | (7.00) | — | (10.05) | (0.31) | (0.61) | (50.43) | (7.28) |
Net Current Asset Value |
76.72 | 26.45 | (20.90) | (66.17) | (89.01) | (104.03) | (51.15) | (21.81) | (5.83) | 193.51 |
EV/EBIT |
6.20 | 3.70 | 6.66 | 8.68 | 103.30 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.03 | 0.00 | 0.04 | 0.00 | 0.00 | 1.82 | 0.00 |
Price to Operating Income |
7.98 | 4.79 | 6.54 | 7.78 | 95.77 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
58.49 | 22.38 | 13.47 | 8.59 | 6.44 | 4.04 | 2.44 | 1.86 | 0.63 | 0.22 |
Cash ROIC |
16.53% | 14.94% | 5.77% | (11.13%) | 10.92% | (4.77%) | 9.37% | (7.03%) | (121.49%) | (33.91%) |
Accounts Receivable Turnover |
5.33 | 5.77 | 5.34 | 6.26 | 8.72 | 8.27 | 10.96 | 16.49 | 4.84 | — |
Accounts Payable Turnover |
11.01 | 10.39 | 9.41 | 6.26 | 5.48 | 2.52 | 1.85 | 1.43 | 0.23 | 0.06 |
Inventory Turnover |
8.17 | 8.15 | 10.80 | 9.47 | 12.06 | 11.89 | 12.71 | 14.88 | 2.39 | 0.00 |
Average Days of Payables |
31.73 | 31.22 | 40.11 | 42.67 | 64.03 | 111.95 | 190.19 | 218.07 | 1,814.00 | 6,364.47 |
Days of Inventory on Hand |
34.61 | 49.44 | 41.23 | 29.99 | 40.73 | 32.02 | 31.43 | 27.67 | 132.91 | 0.00 |
Average Receivables |
42.83 | 39.92 | 44.09 | 36.44 | 29.03 | 27.22 | 24.83 | 15.22 | 5.72 | — |
Average Payables |
5.28 | 6.20 | 6.66 | 8.81 | 11.63 | 15.63 | 19.93 | 24.19 | 23.86 | 18.92 |
Average Inventory |
7.12 | 7.90 | 5.80 | 5.82 | 5.28 | 3.31 | 2.90 | 2.33 | 2.33 | — |
Average Assets |
214.82 | 221.93 | 226.29 | 224.32 | 235.40 | 239.56 | 247.01 | 212.32 | 209.16 | 246.32 |
Average Common Equity |
111.23 | 72.78 | 37.53 | 9.58 | (4.20) | 5.76 | 25.88 | 43.80 | 131.56 | 207.92 |
Columns are period end dates